A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Trial Profile

A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2017

At a glance

  • Drugs OPC 1 (Primary)
  • Indications Spinal cord injuries
  • Focus Adverse reactions; Proof of concept
  • Acronyms SCi-STAR; SCiSTAR
  • Sponsors Asterias Biotherapeutics
  • Most Recent Events

    • 19 Dec 2017 According to an Asterias Biotherapeutics media release, company anticipates expanding the efficacy dataset from the current six subjects in Cohort 2 to a total of 22 subjects by the end of 2018.
    • 19 Dec 2017 According to an Asterias Biotherapeutics media release, comany intends to report 6-month data from Cohort 3 and Cohort 4 in February 2018, and the 12-month data from Cohorts 3 and 4 in August 2018. The company expects to report the six-month top-line readout for the entire study in June 2018 and 12-month top-line readout for the entire study in December 2018.
    • 19 Dec 2017 According to an Asterias Biotherapeutics media release, enrollment and dosing of the last patient has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top